Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

(NASDAQ:EXEL) ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company’s drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's